Merck & Co Inc $ 83.38 1.21 (1.47%)
Merck & Co Inc News and Headlines -
Brandes, who is now retired, is a Benjamin Graham disciple. As such, his firm seeks to purchase out-of-favor securities that are trading at discounts to their intrinsic values, and then holds them until the market recognizes their true worth.
On Dec. 31, the firm purchased an additional 381,534 shares of the Brazillian aircraft and defense manufacturer. The purchase boosted the holding by 1.57%. On the day of
The three securities listed below could be of interest to investors, as their forward price-earnings ratios are lower than the S&P 500's historical average of 15. The projections of future earnings are based on data from Morningstar analysts.
Merck & Co. Inc
The first stock that qualifies is Merck & Co. Inc (MRK), a Kenilworth, New Jersey-based drug giant.
Merck has a forward price-earnings ratio of 12.80 (versus the industry median of 18.61), which results from Thursday's closing price of $84.02 per share and analyst expectations for net earnings per share (EPS) of approximately $6.56 for the next full
Seagen, Inc. (SGEN) has recently been named Biotech of the Year by leading industry publication Biopharma Dive, and investors would no doubt agree. Shares of the Seattle-area firm are up nearly 65% year-to-date, far outpacing the Nasdaq Biotechnology Index, which has climbed about 28% since the beginning of the year. Seagen now trades at $182 per share and has been as high as $215.
In its 24-year history, Seagen (formerly Seattle Genetics) has gone from a small start-up pressed for cash to a recognized leader in the rapidly growing area of targeted cancer medicines. With a market cap of
Howard Marks (Trades, Portfolio) doesn't predict market downturns, but he does use historical valuations as a proxy for whether or not to be invested in the market. As someone who has spent over 50 years investing in the credit markets, Marks understands how to use history to guide his decision-making. In an interview at a Bloomberg Markets forum in 2016, he answered a question about how investors can use investor sentiment and data to help them with their future actions.
Look out for 'bubble thinking'
Marks believes it is possible to know when a market
In August, analysts and investors were wondering what Bristol-Myers Squibb Co. (BMY) could do to reverse the sales decline for one of its blockbuster drugs. This is certainly a legitimate concern considering revenue from the company's cancer treatment, Optivo, declined 9% year over year in the second quarter and another 2% in the three months ending Sept. 30 to approximately $1.8 billion.
The answer may lie in the use of Optivo—and Merck & Co. Inc.'s (MRK) Keytruda-- in pan-adjuvant situations. In these cases, the two drugs known as PD-1 blockers would be used with patients before or after surgery along
Point72 is a hedge fund that was formed in 2014 when SAC Capital Advisors converted its investment operations into a family office. In 2018, the firm re-opened to external investors. Point72 invests via a wide range of asset classes and strategies worldwide. Its core investing strategy is based on bottom-up research with a focus on fundamentals and macroeconomic conditions. Steven Cohen (Trades, Portfolio) serves as the President, CEO and Chairman of
Among the top 15 pharmaceutical companies by sales, Merck & Co. Inc's. (MRK) revenue has been hit the hardest by Covid-19.
EvaluatePharma reported that since the beginning of the global lockdown caused by the pandemic, analyst forecasts for 2020 product sales have dropped by $4.9 billion for the top 15 drug companies. Merck is forecasted to take the biggest blow-- $1.25 billion-- due in great part to the fact that two out of every three of the company's products have to be administered by a physician. With nearly all but only the most essential office visits curtailed, patients aren't getting
Investors who focus on growth may be interested in the following stocks since their price-earnings ratios are trading below 20 and their trailing 12-month earnings per share have grown substantially over the past year.
The first company investors may be interested in is Merck & Co. Inc. (MRK), the Kenilworth, New Jersey-based drug giant.
The company's trailing 12-month net earnings have grown by 26.3% on a year-over-year basis to $4.52 per share as of the third quarter of 2020, up from $3.58 per share in the same quarter of 2019.
The price-earnings ratio was 17.79 (versus the industry median
Merck & Co. Inc.
The firm reduced its stake in Merck & Co. Inc. (MRK) by 57.09%. The trade had an impact of -1.03% on the portfolio.
The developer of pharmaceutical products has a market cap of $203.39 billion and an enterprise value of $224.86 billion.
GuruFocus gives the company a profitability and growth rating of 7 out of 10. The return on equity of 42.41% and return
Previously, I took a look at six of the nine public Chinese biotechnology companies that are projected to become major international competitors in the coming years, according to FiercePharma. Now let's take a look at the prospects for the last three on the list.
Shanghai Junshi Biosciences Co. Ltd. (HKSE:01877)
Junshi Biosciences is another Chinese company -- Innovent Biologics Inc. (HKSE:01801) being the other-- with a drug in the large market for PD-1 inhibitors. But the company's Tuoyi is unique in that it is the first to get approved in China—or anywhere else--and also the first China-made product of its
In a GuruFocus article on Nov. 17, I took a look at three of the nine public Chinese biotechnology companies that are projected to become major international competitors in the coming years, according to FiercePharma. In this article, let's take a look at the prospects for numbers four through six on the list.
Shanghai-based Hua Medicine (HKSE:02552) is somewhat of an outlier on the list since the company is working on drugs for diabetes and central nervous system disorders (unlike the others on the list whose focus is cancer).
Hua is banking heavily on its diabetes
Pharmaceutical giant Merck & Co. Inc. (MRK) reported earnings results at end of October that topped what Wall Street analysts had expected. The company also raised its guidance for the second consecutive quarter. Merck followed this up with a dividend increase earlier this week.
I take the beat and raise along with a dividend increase as a bullish sign for Merck. Let's look at the company's most recent earnings along with its valuation to see why I believe this is a good time to buy.
Merck reported third-quarter earnings results on Oct. 27. Revenue improved 1.2% to
Warren Buffett (Trades, Portfolio)'s Berkshire Hathaway (BRK.A) (BRK.B) filed its 13F report for the third quarter on Monday this week. The announcement revealed that the Oracle of Omaha made some exciting changes to his portfolio during the reported period, including several investments in pharmaceutical companies.
Before we continue, investors should note that this filing only provides a snapshot of the portfolio at one point in time. It details the equity positions in the portfolio as of the end of September 2020. It does not include any cash or credit holdings or any changes made after the quarter
With more than $140 billion to spend on stocks, the renowned guru and his two portfolio managers, Ted Weschler and Todd Combs, entered six new positions during the quarter, which were mainly biotech companies. In addition to the previously revealed stake in Snowflake Inc. (SNOW), Berkshire invested in AbbVie Inc. (ABBV), Merck & Co. Inc. (MRK), Bristol-Myers Squibb Co. (BMY), T-Mobile US Inc. (TMUS) and Pfizer Inc. (PFE).
As previously disclosed in July and
Kahn Brothers (Trades, Portfolio) has released its third-quarter portfolio. Throughout the portfolio holdings were reduced or sold completely, with the largest changes coming from Merck & Co. Inc. (MRK), Bristol-Myers Squibb Company (BMY), GlaxoSmithKline PLC (GSK), Citigroup Inc. (C) and Seaboard Corp. (SEB).
The firm, founded by the late Irving Kahn and his two brothers, has evolved from Benjamin Graham's model of value investing into a contrarian value strategy. It now focuses on metrics such as margin of safety and long-term capital appreciation to serve institutional and high net worth clients.
At the end
AbbVie Inc. (ABBV), a name I have felt is undervalued for some time, reported third-quarter earnings results Friday morning that easily topped Wall Street's estimates. The company also gave yet another double-digit dividend increase.
With all the positives going for the company, AbbVie still looks incredibly undervalued. This is why, in combination with the company's pipeline and high yield, I feel that AbbVie should be at the top of the list for investors looking for exposure to the health care industry.
AbbVie's adjusted earnings per share of $2.83 was an increase of 50 cents, or
After establishing a holding in Bellus Health Inc. (BLU) during the second quarter, billionaire investor Steven Cohen (Trades, Portfolio) disclosed earlier this week his firm, Point72 Asset Management, upped the position by 1,712.12%.
In order to generate superior risk-adjusted returns, the guru's Stamford, Connecticut-based firm invests in a wide range of asset classes worldwide. Its long-short strategy is based on bottom-up research processes focusing on fundamentals and macroeconomic conditions.
According to GuruFocus Real-Time Picks, a Premium feature, Cohen invested in 5.87 million shares of the Canadian biotech company on Oct. 22, impacting the equity portfolio by
Consumer staple giant Procter & Gamble Co. (PG) recently reported earnings results that delivered an organic growth rate that was more than twice that of Wall Street's expectations.
Excellent growth combined with a long history of dividend growth is one of the reasons that Procter & Gamble is a favorite amongst dividend growth investors. I believe the most recent quarter shows the strength of Procter & Gamble's business, and that the company will continue to raise its dividend. Thus, I added to my position on Oct. 20 at a price of $142.47, even as the stock has become overvalued.
Point72 Asset Management leader Steven Cohen (Trades, Portfolio) revealed late last week his firm upped its stake in Dave & Buster's Entertainment Inc. (PLAY) by 354.76% and increased its Fulcrum Therapeutics Inc. (FULC) position by 430.12%.
With the goal of generating superior risk-adjusted returns, the guru's Stamford, Connecticut-based firm invests in a wide range of asset classes worldwide. Its long-short strategy is based on bottom-up research processes focusing on fundamentals and macroeconomic conditions.
Dave & Buster's Entertainment
According to GuruFocus Real-Time Picks, a Premium feature, Cohen invested in an additional 2.7 million shares of Dave &
Pfizer Inc.'s (PFE) quest for an effective Covid-19 vaccine is front and center in the news—rightfully so considering the urgent health care solutions needed due to the pandemic. But the fourth-biggest vaccine manufacturer in the world announced during a virtual investor event on Monday that it also has several inoculations in phase 3 testing that should make it an even bigger market player.
One of the vaccines is a follow-up to the company's Prevnar, the best-selling pneumonia vaccine in the world with revenues of nearly $6 billion last year. FiercePharma reported that SVB Leerink analysts wrote to clients in a